Tristel Secures FDA Clearance for Ophthalmic Disinfectant in US Market

Tristel ( (GB:TSTL) ) just unveiled an update.

Tristel plc has received FDA clearance for its Tristel OPH, a high-level disinfectant foam for ophthalmic medical devices, marking a significant advancement in the US market. This clearance allows Tristel to address the inefficiencies and safety concerns of existing disinfection methods, offering a faster and safer alternative that is compatible with widely used devices. The company has already established local manufacturing in the US and is poised to support early adopters, potentially transforming ophthalmic disinfection practices in North America.

Spark’s Take on GB:TSTL Stock

According to Spark, TipRanks’ AI Analyst, GB:TSTL is a Outperform.

Tristel scores well overall due to its strong financial health and positive corporate events, which are primary drivers of the company’s promising outlook. However, caution is advised due to mixed technical indicators suggesting potential short-term volatility. The balanced valuation adds support, making Tristel a strong candidate for long-term investment.

To see Spark’s full report on GB:TSTL stock, click here.

More about Tristel

Tristel plc is a global infection prevention company specializing in the manufacture and supply of products using its proprietary chlorine dioxide chemistry. It is a market leader in manual decontamination of medical devices and offers sporicidal surface disinfection products. The company operates globally, with its head office in Snailwell, near Cambridge, and employs approximately 270 people across 16 subsidiaries, selling into over 40 countries. Tristel aims for annual revenue growth of 10% to 15% and maintains a profitable business with no debt.

Average Trading Volume: 110,818

Technical Sentiment Signal: Buy

Current Market Cap: £188.4M

Learn more about TSTL stock on TipRanks’ Stock Analysis page.